{"id":3087,"date":"2026-04-10T08:29:02","date_gmt":"2026-04-10T05:29:02","guid":{"rendered":"https:\/\/merkezlaboratuvari.com\/test-listesi\/c-peptid-30-dk-2\/"},"modified":"2026-04-16T15:47:56","modified_gmt":"2026-04-16T12:47:56","slug":"c-peptid-30-dk","status":"publish","type":"page","link":"https:\/\/merkezlaboratuvari.com\/ar\/test-listesi\/c-peptid-30-dk\/","title":{"rendered":"C-Peptid, 30. dk."},"content":{"rendered":"<h1>C-Peptid, 30. dk.<\/h1>\n<h2>Laboratuvar Bilgileri<\/h2>\n<ul>\n<li><strong>Yeni Kod:<\/strong> BIO7968<\/li>\n<li><strong>SUT Kodu:<\/strong> L101830<\/li>\n<li><strong>Eski Kod:<\/strong> HR0122<\/li>\n<li><strong>Kategori:<\/strong> \u0643\u064a\u0645\u064a\u0627\u0621 \u062d\u064a\u0648\u064a\u0629<\/li>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> Ayn\u0131 g\u00fcn 18:00<\/li>\n<\/ul>\n<h2>C-Peptid, 30. dk. Testi Nedir?<\/h2>\n<p>C-Peptid, 30. dk., laboratuvar ortam\u0131nda de\u011ferlendirilen bir biyokimya testidir. De\u011ferlendirme \u00e7o\u011fu zaman serum \u00f6rne\u011fi \u00fczerinden planlan\u0131r.<\/p>\n<p>C-peptid, pankreas beta h\u00fccreleri taraf\u0131ndan proins\u00fclinden ins\u00fclin olu\u015furken a\u00e7\u0131\u011fa \u00e7\u0131kan bir par\u00e7ad\u0131r. Endojen ins\u00fclin \u00fcretimini g\u00f6stermede yararl\u0131d\u0131r; d\u0131\u015far\u0131dan verilen ins\u00fclinden etkilenmez. Bu nedenle hipoglisemi nedenlerinin ara\u015ft\u0131r\u0131lmas\u0131nda, diyabet tipinin ay\u0131r\u0131m\u0131nda ve pankreas beta h\u00fccre rezervinin de\u011ferlendirilmesinde kullan\u0131l\u0131r.<\/p>\n<p>Bu testin klinik anlam\u0131; istem nedeni, hastan\u0131n yak\u0131nmalar\u0131, ya\u015f\u0131, e\u015flik eden hastal\u0131klar\u0131, kullan\u0131lan y\u00f6ntem ve di\u011fer laboratuvar bulgular\u0131 ile birlikte de\u011ferlendirilir. Bu nedenle sonu\u00e7, tek ba\u015f\u0131na de\u011fil, b\u00fct\u00fcnc\u00fcl t\u0131bbi \u00e7er\u00e7eve i\u00e7inde yorumlanmal\u0131d\u0131r.<\/p>\n<h2>C-Peptid, 30. dk. Hangi Durumlarda \u0130stenir?<\/h2>\n<p>C-Peptid, 30. dk. testi, hekim taraf\u0131ndan klinik gereklilik g\u00f6r\u00fclen durumlarda istenebilir. \u0130stem gerek\u00e7esi hastan\u0131n mevcut tablosuna g\u00f6re de\u011fi\u015febilir.<\/p>\n<ul>\n<li>Hipoglisemi nedenlerinin ara\u015ft\u0131r\u0131lmas\u0131nda<\/li>\n<li>\u0130ns\u00fclinoma \u015f\u00fcphesinde<\/li>\n<li>Tip 1 ve tip 2 diyabet ayr\u0131m\u0131nda yard\u0131mc\u0131 olarak<\/li>\n<li>Beta h\u00fccre rezervinin de\u011ferlendirilmesinde<\/li>\n<li>\u0130ns\u00fclin tedavisi plan\u0131 veya diyabet izleminde se\u00e7ilmi\u015f durumlarda<\/li>\n<\/ul>\n<p>Ayn\u0131 test farkl\u0131 hastalarda farkl\u0131 klinik sorulara yan\u0131t aramak amac\u0131yla kullan\u0131labildi\u011fi i\u00e7in, nihai de\u011ferlendirme her zaman ki\u015fisel t\u0131bbi \u00f6yk\u00fc ve muayene bulgular\u0131 ile birlikte yap\u0131lmal\u0131d\u0131r.<\/p>\n<h2>C-Peptid, 30. dk. Testi \u00d6ncesi Haz\u0131rl\u0131k<\/h2>\n<p>Haz\u0131rl\u0131k gereksinimi; testin t\u00fcr\u00fcne, numune yap\u0131s\u0131na ve laboratuvar\u0131n \u00e7al\u0131\u015fma kurallar\u0131na g\u00f6re de\u011fi\u015febilir. Test \u00f6ncesinde laboratuvar\u0131n ve hekimin verdi\u011fi talimatlar esas al\u0131nmal\u0131d\u0131r.<\/p>\n<ul>\n<li>A\u00e7l\u0131k \u00f6rne\u011fi istenebilir; laboratuvar talimat\u0131 esas al\u0131nmal\u0131d\u0131r.<\/li>\n<li>Baz\u0131 olgularda tokluk sonras\u0131 veya uyar\u0131 sonras\u0131 \u00f6l\u00e7\u00fcm yap\u0131labilir.<\/li>\n<li>E\u015f zamanl\u0131 glukoz ve bazen ins\u00fclin d\u00fczeyi ile birlikte yorumland\u0131\u011f\u0131 i\u00e7in \u00f6rnek zamanlamas\u0131 \u00f6nemlidir.<\/li>\n<\/ul>\n<p>Kullan\u0131lan ila\u00e7lar, takviyeler, yak\u0131n d\u00f6nemde ge\u00e7irilen hastal\u0131klar ve e\u015flik eden kronik durumlar sonucun yorumlanmas\u0131n\u0131 etkileyebilece\u011fi i\u00e7in sa\u011fl\u0131k profesyoneli ile payla\u015f\u0131lmal\u0131d\u0131r.<\/p>\n<h2>C-Peptid, 30. dk. Testi Nas\u0131l Yap\u0131l\u0131r?<\/h2>\n<p>C-Peptid, 30. dk. testi, uygun biyolojik \u00f6rnek al\u0131nd\u0131ktan sonra laboratuvar\u0131n belirledi\u011fi y\u00f6ntemle \u00e7al\u0131\u015f\u0131l\u0131r. Numunenin do\u011fru zamanda, uygun kapta ve uygun ta\u015f\u0131ma ko\u015fullar\u0131nda ula\u015ft\u0131r\u0131lmas\u0131 test kalitesi a\u00e7\u0131s\u0131ndan \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> Ayn\u0131 g\u00fcn 18:00<\/li>\n<\/ul>\n<ul>\n<li>Genellikle serum \u00f6rne\u011finde \u00e7al\u0131\u015f\u0131l\u0131r.<\/li>\n<li>Baz\u0131 laboratuvarlarda zamanl\u0131 dinamik \u00f6rnekleme yap\u0131labilir.<\/li>\n<li>Sonu\u00e7 \u00e7o\u011fu zaman glukoz d\u00fczeyiyle birlikte de\u011ferlendirilir.<\/li>\n<\/ul>\n<p>Baz\u0131 durumlarda \u00f6rnek kalitesi, numune miktar\u0131, ta\u015f\u0131ma s\u00fcresi veya teknik tekrar gereksinimi raporlama s\u00fcresini ve sonucun g\u00fcvenilirli\u011fini etkileyebilir.<\/p>\n<h2>C-Peptid, 30. dk. Testi Ka\u00e7 G\u00fcnde \u00c7\u0131kar?<\/h2>\n<p>Mevcut laboratuvar bilgisine g\u00f6re bu test i\u00e7in raporlama s\u00fcresi: <strong>Ayn\u0131 g\u00fcn 18:00<\/strong> \u015feklindedir.<\/p>\n<p>Numunenin kabul zaman\u0131, laboratuvar\u0131n \u00e7al\u0131\u015fma plan\u0131, resmi tatiller veya gerekti\u011finde tekrar \u00e7al\u0131\u015fma gibi etkenler sonucu etkileyebilece\u011fi i\u00e7in en g\u00fcncel bilgi rapor tarihi \u00fczerinden de\u011ferlendirilmelidir.<\/p>\n<h2>Referans De\u011ferleri ve Sonu\u00e7lar\u0131n De\u011ferlendirilmesi<\/h2>\n<p>Referans aral\u0131klar\u0131 y\u00f6nteme g\u00f6re de\u011fi\u015fmekle birlikte eri\u015fkin serum i\u00e7in bir\u00e7ok laboratuvar yakla\u015f\u0131k `0.5-2.0 ng\/mL` veya benzer aral\u0131klar kullan\u0131r. A\u00e7l\u0131k, tokluk ve dinamik test ko\u015fullar\u0131na g\u00f6re yorum de\u011fi\u015fir; rapordaki laboratuvar referans\u0131 esas al\u0131nmal\u0131d\u0131r.<\/p>\n<p>Referans bilgileri; kullan\u0131lan y\u00f6ntem, ya\u015f grubu, biyolojik \u00f6rnek tipi ve laboratuvar standard\u0131na g\u00f6re de\u011fi\u015febilece\u011finden, rapor \u00fczerinde yer alan laboratuvar yorumu esas al\u0131nmal\u0131d\u0131r.<\/p>\n<h2>C-Peptid, 30. dk. Sonucu Nas\u0131l Yorumlan\u0131r?<\/h2>\n<p>Test sonucu tek ba\u015f\u0131na kesin tan\u0131 koydurmaz. Sonu\u00e7; klinik bulgular, di\u011fer laboratuvar verileri ve gerekli g\u00f6r\u00fcld\u00fc\u011f\u00fcnde ek incelemeler ile birlikte de\u011ferlendirilir.<\/p>\n<ul>\n<li>Y\u00fcksek C-peptid, endojen ins\u00fclin \u00fcretiminin artt\u0131\u011f\u0131n\u0131 d\u00fc\u015f\u00fcnd\u00fcrebilir.<\/li>\n<li>D\u00fc\u015f\u00fck C-peptid, beta h\u00fccre rezervinin azald\u0131\u011f\u0131n\u0131 veya endojen ins\u00fclin \u00fcretiminin yetersiz oldu\u011funu g\u00f6sterebilir.<\/li>\n<li>Hipoglisemide y\u00fcksek ins\u00fclin ve y\u00fcksek C-peptid endojen hiperins\u00fclinizmi d\u00fc\u015f\u00fcnd\u00fcr\u00fcr; y\u00fcksek ins\u00fclin ve d\u00fc\u015f\u00fck C-peptid d\u0131\u015far\u0131dan ins\u00fclin kullan\u0131m\u0131n\u0131 destekleyebilir.<\/li>\n<li>Sonu\u00e7lar glukoz, ins\u00fclin, proins\u00fclin ve klinik tablo ile birlikte de\u011ferlendirilmelidir.<\/li>\n<\/ul>\n<p>\u00d6zellikle s\u0131n\u0131rda, d\u00fc\u015f\u00fck d\u00fczeyli veya beklenmeyen sonu\u00e7larda klinik korelasyon gerekir. Gerekti\u011finde tekrar test, panel de\u011ferlendirmesi veya ek laboratuvar incelemeleri planlanabilir.<\/p>\n<h2>Testin S\u0131n\u0131rl\u0131l\u0131klar\u0131<\/h2>\n<p>Her laboratuvar testinde oldu\u011fu gibi bu incelemenin de baz\u0131 s\u0131n\u0131rl\u0131l\u0131klar\u0131 vard\u0131r. Sonu\u00e7; \u00f6rnek kalitesi, \u00f6rnekleme zaman\u0131, ta\u015f\u0131ma ko\u015fullar\u0131 ve klinik ba\u011flamdan etkilenebilir.<\/p>\n<ul>\n<li>Tek bir laboratuvar sonucu, klinik \u00e7er\u00e7eve d\u0131\u015f\u0131nda eksik yorumlanabilir.<\/li>\n<li>Uygun olmayan numune kalitesi sonucun g\u00fcvenilirli\u011fini azaltabilir.<\/li>\n<li>Gerekti\u011finde ek testler olmadan tek ba\u015f\u0131na karar vermek yan\u0131lt\u0131c\u0131 olabilir.<\/li>\n<\/ul>\n<h2>Olas\u0131 Riskler<\/h2>\n<p>Risk \u00e7o\u011funlukla numune alma ve numune y\u00f6netimi s\u00fcreci ile ili\u015fkilidir. Testin kendisinden \u00e7ok, \u00f6rne\u011fin al\u0131nmas\u0131 ve uygun ko\u015fullarda \u00e7al\u0131\u015f\u0131lmas\u0131 \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li>Kan al\u0131m\u0131na ba\u011fl\u0131 hafif a\u011fr\u0131, morarma veya nadiren enfeksiyon olabilir.<\/li>\n<li>A\u00e7l\u0131k \u015fart\u0131na uyulmamas\u0131 yorumu zorla\u015ft\u0131rabilir.<\/li>\n<li>B\u00f6brek fonksiyon bozuklu\u011fu C-peptid d\u00fczeylerini etkileyebilir.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>C-Peptid, 30. dk. Laboratuvar Bilgileri Yeni Kod: BIO7968 SUT Kodu: L101830 Eski Kod: HR0122 Kategori: Biyokimya Numune T\u00fcr\u00fc: Serum Numune Kab\u0131: Sar\u0131 Kapak \u00c7al\u0131\u015fma G\u00fcn\u00fc: Her g\u00fcn \u00d6nemli Kriter: \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r. Raporlama Tarihi: Ayn\u0131 g\u00fcn 18:00 C-Peptid, 30. dk. Testi Nedir? C-Peptid, 30. dk., laboratuvar [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":5,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"test_category":"Biyokimya","test_kodu":"BIO7968","numune_turu":"Serum","numune_kabi":"Sar\u0131 Kapak","calisma_gunu":"Her g\u00fcn","onemli_kriter":"\u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.","raporlama_tarihi":"Ayn\u0131 g\u00fcn 18:00","numune_red_kriterleri":"","aktarim_kodu":"","loinc_kodu":"","sut_kodu":"L101830","akredite":"","numune_miktari":"","alternatif_ornek":"","numune_alinma_sekli":"","stabilite_ozellikleri":"","calisma_yontemi":"","test_bilgisi":"","footnotes":""},"class_list":["post-3087","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/comments?post=3087"}],"version-history":[{"count":2,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3087\/revisions"}],"predecessor-version":[{"id":7456,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3087\/revisions\/7456"}],"up":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/5"}],"wp:attachment":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/media?parent=3087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}